Skip to main content

EGFR Gene Mutation clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

    Sorry, in progress, not accepting new patients

    This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and/or bad, it has on EGFR-mutated lung cancer.

    San Francisco, California

Our lead scientists for EGFR Gene Mutation research studies include .

Last updated: